The Lawrence and Isabel Barnett Drug Development Program supports academic and industry investigators conducting preclinical studies of new or repurposed ALS therapies to advance them toward clinical testing.
The Hoffman ALS Clinical Trial Awards Program supports researchers conducting biomarker-driven early trials of ALS therapies and imaging tracers to advance treatment development and care.
Drug Development RFP supports researchers and clinicians developing drugs and devices through IND-enabling studies and early clinical trials to advance treatments for Alzheimer’s disease and related dementias.
Longitude Prize on ALS supports multidisciplinary teams using AI to discover, prioritise and validate therapeutic targets, seeking the strongest evidence of potential to advance ALS treatment.
This grant will fund research using data from expanded access to investigational drugs for ALS patients who are ineligible for clinical trials, aiming to improve prevention, diagnosis, or treatment of ALS.
ADDF-Harrington Scholar Program supports academic researchers with drug-development funding and expert guidance to advance novel medicines that treat, prevent, slow, or reverse Alzheimer’s and related dementias.